Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 49, 2010, Pages 21093-21097

  Di Gennaro, Antonio ^a   Wagsáter, Dick ^a   Máyránpáá, Mikko I ^b,c   Gabrielsen, Anders ^a   Swedenborg, Jesper ^d   Hamsten, Anders ^a   Samuelsson, Bengt ^a   Eriksson, Per ^a   Haeggström, Jesper Z ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b WIHURI RESEARCH INSTITUTE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Eicosanoid; Inflammation

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; GELATINASE A; GELATINASE B; LEUKOTRIENE A4; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE D4; MESSENGER RNA; MONTELUKAST; PEPTIDOLEUKOTRIENE;

ABDOMINAL AORTA ANEURYSM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME RELEASE; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; MACROPHAGE; MAST CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

5-LIPOXYGENASE-ACTIVATING PROTEINS; AORTIC ANEURYSM, ABDOMINAL; ARACHIDONATE 5-LIPOXYGENASE; ATHEROSCLEROSIS; CYSTEINE; GLUTATHIONE TRANSFERASE; HUMANS; LEUKOTRIENES; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; RNA, MESSENGER;

EID: 78650465572     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1015166107     Document Type: Article

References (37)

1. Funk CD (2001) Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294:1871-1875.
2. Samuelsson B (1983) Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 220:568-575.
3. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T (1997) A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387:620-624.
4. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T (2000) A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 192:421-432.
5. Lynch KR, et al. (1999) Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399:789-793.
6. Heise CE, et al. (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275:30531-30536.
7. Peters-Golden M, Henderson WR, Jr (2007) Leukotrienes. N Engl J Med 357: 1841-1854.
8. Sinha S, Frishman WH (1998) Matrix metalloproteinases and abdominal aortic aneurysms: A potential therapeutic target. J Clin Pharmacol 38:1077-1088.
9. Longo GM, et al. (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110:625-632.
10. Rizas KD, Ippagunta N, Tilson MD, 3rd (2009) Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm. Cardiol Rev 17:201-210.
11. Fontaine V, et al. (2002) Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 161:1701-1710.
12. Houard X, et al. (2007) Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms. J Pathol 212:20-28.
13. Middleton RK, et al. (2007) The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg 45:574-580.
14. Houard X, Ollivier V, Louedec L, Michel JB, Bäck M (2009) Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. FASEB J 23:1376-1383.
15. Kazi M, et al. (2003) Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J Vasc Surg 38:1283-1292.
16. Funk CD (2005) Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 4:664-672.
17. Qiu H, et al. (2006) Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 103:8161-8166.
18. Helgadottir A, et al. (2004) The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36:233-239.
19. Zhao L, et al. (2004) The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia- dependent aortic aneurysm. Nat Med 10:966-973.
20. Ahluwalia N, et al. (2007) Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol 179:691-697.
21. Cao RY, Adams MA, Habenicht AJ, Funk CD (2007) Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice. Prostaglandins Other Lipid Mediat 84:34-42.
22. Matusik P, et al. (2010) Architecture of intraluminal thrombus removed from abdominal aortic aneurysm. J Thromb Thrombolysis 30:7-9.
23. Ichiyama T, et al. (2007) Cysteinyl leukotrienes enhance tumour necrosis factor-alphainduced matrix metalloproteinase-9 in human monocytes/macrophages. Clin Exp Allergy 37:608-614.
24. Drazen JM, Israel E, O'Byrne PM (1999) Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197-206.
25. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH (2008) What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 29:72-78.
26. Folkesson M, et al. (2007) Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb Haemost 98:427-433.
27. Kristo F, et al. (2010) Pharmacological inhibition of BLT1 diminishes early abdominal aneurysm formation. Atherosclerosis 210:107-113.
28. Funk CD, Cao RY, Zhao L, Habenicht AJ (2006) Is there a role for the macrophage 5- lipoxygenase pathway in aortic aneurysm development in apolipoprotein E-deficient mice? Ann N Y Acad Sci 1085:151-160.
29. Bingham CO, 3rd, Austen KF (2000) Mast-cell responses in the development of asthma. J Allergy Clin Immunol 105:S527-S534.
30. Mellor EA, Austen KF, Boyce JA (2002) Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med 195: 583-592.
31. Ichiyama T, et al. (2005) Cysteinyl leukotrienes induce monocyte chemoattractant protein 1 in human monocytes/macrophages. Clin Exp Allergy 35:1214-1219.
32. Ichiyama T, et al. (2009) Cysteinyl leukotrienes induce macrophage inflammatory protein-1 in human monocytes/macrophages. Int Arch Allergy Immunol 148:147-153.
33. Serhan CN (2007) Resolution phase of inflammation: novel endogenous antiinflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25: 101-137.
34. Rao NL, et al. (2010) Leukotriene A(4) hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 181:899-907.
35. Maekawa A, Kanaoka Y, Xing W, Austen KF (2008) Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci USA 105:16695-16700.
36. Paruchuri S, et al. (2009) Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 206:2543-2555.
37. Maekawa A, Balestrieri B, Austen KF, Kanaoka Y (2009) GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci USA 106:11685-11690.